Immunology

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

By

The FDA granted the drug Priority Review status just last week.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

By

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

By

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

News hints at BMS-Merck PD-1 lung cancer tussle

News hints at BMS-Merck PD-1 lung cancer tussle

By

News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.

Mallinckrodt plans expansion of commercial staff

The specialty biopharma firm says it's hiring new commercial managers after a buying spree.

J&J subsidiary inks $35M RNA deal

The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.

Who will win the Opdivo-Keytruda coverage clash?

Who will win the Opdivo-Keytruda coverage clash?

By

A focus on the existing Yervoy prescribing community could help Bristol-Myers Squibb drive sales of Opdivo past rival Keytruda, one analyst argues.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

By

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

Positive lymphoma trials point to expanded role for immune therapies

Positive lymphoma trials point to expanded role for immune therapies

By

Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.

AbbVie oncology pipeline continues to show progress

AbbVie oncology pipeline continues to show progress

By

Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.

Amgen releases Humira biosimilar data

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Merck scores first US PD-1 approval

Merck scores first US PD-1 approval

By By

The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

BMS enters two immuno-oncology deals

The drugmaker has paired up with Incyte and CytomyX in two separate deals.

Takeda jumps into Humira space

Takeda jumps into Humira space

By

The FDA's approval of Takeda's Entyvio puts the drugmaker in the ulcerative colititis and Crohn's mix of prescription treatments.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Novartis expands immuno-oncology presence

Novartis expands immuno-oncology presence

By

The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

Analysts put weight on BMS in oncology

Analysts put weight on BMS in oncology

By

Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.

Drugmakers carve out immuno-oncology turf

Drugmakers carve out immuno-oncology turf

By

Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.

Takeda may be poised to expand IBS treatment category

By

Phase III results of its Crohn's and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters